Lymphoma

Lymphoma

We’re here for you. Call us at 844-346-7222 or

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.

60 Clinical Trials
Lymphoma NA Active
nct/study# NCT04981795 / MOR208C414

Prospective Multicenter Observational Study Of Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Starting Second- Or Third-Line Therapy And Not Receiving Autologous Stem Cell Transplant (REAL-MIND)

Learn More
Lymphoma Phase II Accepting Patients
nct/study# NCT03113500 / COH-17058

A Phase 2 Study Of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, And Prednisone (CHEP-BV) Followed By BV Consolidation In Patients With CD30-Positive Peripheral T-Cell Lymphomas

Learn More
Lymphoma Phase II Accepting Patients
nct/study# NCT03712202 / COH18157

A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin And Nivolumab Incorporated And Radiation Free Management Of Early Stage Classical Hodgkin Lymphoma (Chl)

Learn More
Lymphoma Phase I Accepting Patients
nct/study# NCT03952078 / CPI-818-001

A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, An Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, In Subjects With Relapsed/Refractory T-Cell And Follicular B-Cell Non-Hodgkin Lymphoma

Learn More
Lymphoma Phase I Accepting Patients
nct/study# NCT02732275 / DS3201-A-J101

A Phase 1 Multiple Ascending Dose Study Of DS-3201b In Subjects With Lymphomas

Learn More
Lymphoma Phase I Accepting Patients
nct/study# NCT02616965 / HM-085

A Phase I Trial Assessing The Feasibility Of Romidepsin Combined With Brentuximab Vedotin For Patients With Requiring Systemic Therapy For Cutaneous T-Cell Lymphoma

Learn More

We are here for you

For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.